Emilio Portaccio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7018932/publications.pdf

Version: 2024-02-01

125 papers	6,540 citations	57631 44 h-index	74018 75 g-index
128 all docs	128 docs citations	128 times ranked	5148 citing authors

#	Article	IF	Citations
1	Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. Journal of the Neurological Sciences, 2006, 245, 41-46.	0.3	465
2	The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Multiple Sclerosis Journal, 2006, 12, 787-793.	1.4	343
3	New natural history of interferon-Î²-treated relapsing multiple sclerosis. Annals of Neurology, 2007, 61, 300-306.	2.8	251
4	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.5	227
5	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Multiple Sclerosis Journal, 2017, 23, 1258-1267.	1.4	209
6	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2007, 64, 1157.	4.9	203
7	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309903.	0.9	162
8	Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Multiple Sclerosis Journal, 2010, 16, 1474-1482.	1.4	157
9	Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nature Reviews Neuroscience, 2018, 19, 599-609.	4.9	151
10	Benign multiple sclerosis. Journal of Neurology, 2006, 253, 1054-1059.	1.8	147
11	Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Multiple Sclerosis Journal, 2010, 16, 62-67.	1.4	144
12	Cognitive changes in multiple sclerosis. Expert Review of Neurotherapeutics, 2008, 8, 1585-1596.	1.4	141
13	Cognitive reserve and cortical atrophy in multiple sclerosis. Neurology, 2013, 80, 1728-1733.	1.5	113
14	Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. Neurological Sciences, 2009, 30, 15-20.	0.9	110
15	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. Multiple Sclerosis Journal, 2014, 20, 91-98.	1.4	103
16	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.5	102
17	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
18	Long-Term Adherence to Interferon Î² Therapy in Relapsing-Remitting Multiple Sclerosis. European Neurology, 2008, 59, 131-135.	0.6	86

#	Article	IF	Citations
19	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology, 2021, 78, 414.	4.5	86
20	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86
21	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	0.8	82
22	Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study. PLoS ONE, 2012, 7, e35843.	1.1	82
23	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	0.8	78
24	Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. PLoS ONE, 2012, 7, e44826.	1.1	78
25	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	1.4	77
26	Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain, 2006, 129, 2008-2016.	3.7	75
27	Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. CNS Drugs, 2015, 29, 207-220.	2.7	75
28	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.5	74
29	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. PLoS ONE, 2011, 6, e19452.	1.1	74
30	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	0.9	66
31	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology, 2013, 80, 2090-2094.	1.5	63
32	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626.	1.4	56
33	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. Neurology, 2014, 82, 1314-1321.	1.5	56
34	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 757-759.	0.9	55
35	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). Journal of the Neurological Sciences, 2013, 331, 94-97.	0.3	53
36	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	3.7	53

#	Article	IF	Citations
37	Reliability, practice effects, and change indices for Raoâ€™s brief repeatable battery. Multiple Sclerosis Journal, 2010, 16, 611-617.	1.4	52
38	Are there protective treatments for cognitive decline in MS?. Journal of the Neurological Sciences, 2006, 245, 183-186.	0.3	51
39	Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 214-219.	1.4	51
40	Anxiety state affects information processing speed in patients with multiple sclerosis. Neurological Sciences, 2014, 35, 559-563.	0.9	51
41	Withdrawal of fingolimod treatment for relapsingâ€“remitting multiple sclerosis: report of six cases. Multiple Sclerosis Journal, 2012, 18, 1636-1639.	1.4	50
42	Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1732-1740.	1.4	48
43	Impact of cognitive impairment on coping strategies in multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 127-130.	0.6	47
44	Management options in multiple sclerosis-associated fatigue. Expert Opinion on Pharmacotherapy, 2012, 13, 207-216.	0.9	46
45	Natalizumab may reduce cognitive changes and brain atrophy rate in relapsingâ€“remitting multiple sclerosis: a prospective, â€˜nonâ€•randomized pilot study. European Journal of Neurology, 2013, 20, 986-990.	1.7	46
46	Clinical outcome measures in multiple sclerosis. Journal of the Neurological Sciences, 2007, 259, 118-122.	0.3	45
47	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	0.9	42
48	Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. Journal of Neuroscience, 2015, 35, 550-558.	1.7	42
49	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	1.8	41
50	Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-Î². Journal of the Neurological Sciences, 2006, 244, 97-102.	0.3	40
51	Score on Coma Recovery Scale-Revised at admission predicts outcome at discharge in intensive rehabilitation after severe brain injury. Brain Injury, 2018, 32, 730-734.	0.6	39
52	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurological Sciences, 2019, 40, 1651-1657.	0.9	39
53	Changes in Neuropsychological Test Performance Over the Workday in Multiple Sclerosis. Clinical Neuropsychologist, 2003, 17, 551-560.	1.5	38
54	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	3.7	38

#	Article	IF	Citations
55	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	2.9	38
56	Safety and tolerability of cyclophosphamide â€˜pulsesâ€™ in multiple sclerosis: a prospective study in a clinical cohort. Multiple Sclerosis Journal, 2003, 9, 446-450.	1.4	37
57	Aging process, adherence to Mediterranean diet and nutritional status in a large cohort of nonagenarians: Effects on endothelial progenitor cells. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 84-90.	1.1	37
58	â€˜Subclinical MSâ€™: followâ€up of four cases. European Journal of Neurology, 2008, 15, 858-861.	1.7	35
59	Improving Compliance with Interferon-Î² Therapy in Patients with Multiple Sclerosis. CNS Drugs, 2009, 23, 453-462.	2.7	33
60	Multiple sclerosis in Italy: cost-of-illness study. Neurological Sciences, 2011, 32, 787-794.	0.9	33
61	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple Sclerosis Journal, 2018, 24, 1234-1242.	1.4	33
62	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	1.4	32
63	Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. PLoS ONE, 2019, 14, e0222929.	1.1	32
64	The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 472-478.	1.4	31
65	The Raoâ€™s Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. Neurological Sciences, 2014, 35, 79-82.	0.9	31
66	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
67	Improvement on the Coma Recovery Scaleâ€“Revised During the First Four Weeks of Hospital Stay Predicts Outcome at Discharge in Intensive Rehabilitation After Severe Brain Injury. Archives of Physical Medicine and Rehabilitation, 2018, 99, 914-919.	0.5	31
68	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Multiple Sclerosis Journal, 2022, 28, 132-138.	1.4	31
69	Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Multiple Sclerosis Journal, 2006, 12, 281-286.	1.4	30
70	Neocortical volume decrease in relapsingâ€“remitting multiple sclerosis with mild cognitive impairment. Journal of the Neurological Sciences, 2006, 245, 195-199.	0.3	30
71	Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1326-1334.	1.4	30
72	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 628-640.	1.4	28

#	Article	IF	Citations
73	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	0.8	27
74	Prognostic value of post-acute EEG in severe disorders of consciousness, using American Clinical Neurophysiology Society terminology. Neurophysiologie Clinique, 2019, 49, 317-327.	1.0	25
75	EEG and Coma Recovery Scaleâ€Revised prediction of neurological outcome in Disorder of Consciousness patients. Acta Neurologica Scandinavica, 2020, 142, 221-228.	1.0	25
76	Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Multiple Sclerosis Journal, 2007, 13, 676-678.	1.4	24
77	Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. Journal of the Neurological Sciences, 2008, 266, 25-30.	0.3	23
78	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.3	23
79	Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. Journal of Neurology, 2013, 260, 1675-1677.	1.8	23
80	Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. Journal of Neuroinflammation, 2013, 10, 94.	3.1	22
81	APOE-Îµ4 is not associated with cognitive impairment in relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1489-1494.	1.4	21
82	Causes of diplopia in the emergency department. European Journal of Emergency Medicine, 2014, 21, 118-124.	0.5	21
83	Breastfeeding and post-partum relapses in multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 1211-1216.	1.4	21
84	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. Multiple Sclerosis Journal, 2021, 27, 39-51.	1.4	21
85	Truly benign multiple sclerosis is rare: letâ€™s stop fooling ourselves-Yes. Multiple Sclerosis Journal, 2012, 18, 13-14.	1.4	20
86	No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1791-1796.	1.4	19
87	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Frontiers in Neurology, 2017, 8, 608.	1.1	19
88	Cognitive Issues in Pediatric Multiple Sclerosis. Brain Sciences, 2021, 11, 442.	1.1	18
89	Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Review of Clinical Immunology, 2013, 9, 683-692.	1.3	17
90	Interobserver agreement on Poserâ€™s and the new McDonaldâ€™s diagnostic criteria for multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 481-485.	1.4	16

#	Article	IF	Citations
91	History of multiple sclerosis in 2 successive pregnancies. Neurology, 2016, 87, 1360-1367.	1.5	16
92	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
93	Cognitive rehabilitation in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 275-278.	0.9	13
94	Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. Neurological Sciences, 2011, 32, 1043-1046.	0.9	13
95	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 2016, 13, 799-805.	2.4	13
96	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 645220.	1.1	13
97	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
98	Decannulation After a Severe Acquired Brain Injury. Archives of Physical Medicine and Rehabilitation, 2020, 101, 1906-1913.	0.5	13
99	Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients. European Neurology, 2009, 61, 177-182.	0.6	12
100	Clinical correlations of CSF single IgG bands. Journal of Neurology, 2005, 252, 1274-1275.	1.8	11
101	ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurologica Scandinavica, 2009, 120, 439-441.	1.0	11
102	Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evidence, 2011, 6, 13.	4.7	11
103	Emotional and neutral verbal memory impairment in Multiple Sclerosis. Journal of the Neurological Sciences, 2014, 341, 28-31.	0.3	11
104	Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series. Multiple Sclerosis Journal, 2021, 27, 198-207.	1.4	10
105	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Molecular Psychiatry, 2022, 27, 1010-1019.	4.1	10
106	Critical illness polyneuromyopathy: Functional impact after severe acquired brain injuries. Acta Neurologica Scandinavica, 2020, 142, 574-584.	1.0	9
107	Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. Neurological Sciences, 2020, 41, 2939-2945.	0.9	8
108	Decannulation and improvement of responsiveness in patients with disorders of consciousness. Neuropsychological Rehabilitation, 2022, 32, 520-536.	1.0	7

#	Article	IF	Citations
109	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.5	7
110	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the â€œbenign statusâ€? A 12-year follow-up study. Multiple Sclerosis and Related Disorders, 2018, 26, 71-73.	0.9	6
111	Impact of occupational complexity on cognitive decline in the oldest-old. Aging and Mental Health, 2021, 25, 1630-1635.	1.5	6
112	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	2.8	6
113	A decline in cognitive function should lead to a change in disease-modifying therapy â€“ No. Multiple Sclerosis Journal, 2018, 24, 1683-1684.	1.4	5
114	Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. Brain Sciences, 2021, 11, 1444.	1.1	5
115	Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. Journal of the Neurological Sciences, 2009, 284, 223.	0.3	4
116	Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?. Expert Review of Neurotherapeutics, 2011, 11, 1243-1246.	1.4	4
117	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. Clinical Neurology and Neurosurgery, 2013, 115, 1044-1048.	0.6	4
118	Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. Developmental Neuropsychology, 2017, 42, 299-308.	1.0	4
119	Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology, 2018, 91, 851-851.	1.5	4
120	The minimal neuropsychological assessment of MS patients (MACFIMS): normative data of the Italian population. Neurological Sciences, 2020, 41, 1489-1496.	0.9	3
121	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. Multiple Sclerosis Journal, 2022, 28, 154-159.	1.4	3
122	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	1.4	3
123	Understanding the pathophysiology of cognitive changes in MS: A step forward. Multiple Sclerosis Journal, 2021, 27, 4-5.	1.4	1
124	RiproducibilitÃ del punteggio EDSS calcolato con un nuovo software dedicato rispetto al metodo tradizionale in uso. Quaderni Italiani Di Psichiatria, 2012, 31, 26-31.	0.1	0
125	Linking structural and functional brain alterations in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 2021, 429, 118314.	0.3	0